Pharmaceutical and medical device manufacturing and capacity
Pharmaceutical and medical device manufacturing and capacity
ANVISA’s RDC 1023/2026 formalizes cannabis active pharmaceutical ingredient exports while the 8th Brazilian Pharmacopoeia edition sets new quality benchmarks, positioning Brazil’s industrial health complex for international market entry.
ANVISA’s approval of the 8th edition of Farmacopeia Brasileira updates national quality standards for medicines and active pharmaceutical ingredients, reshaping registration requirements across Brazil’s pharmaceutical market.
You must be logged in to post a comment.